NGM313: Phase I started

NGM began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single and multiple ascending doses of NGM313 in about 183 healthy overweight or obese volunteers. NGM is developing NGM313 for conditions that include Type II diabetes, obesity and non-alcoholic steatohepatitis (NASH). ...